Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

On the issue of the COVID-19 study being FDA approved to move to a Phase 3 clinical trial... PROVE IT.

You're saying it's so because Christopher Moreau said so...LMAO. As I've already stated, that study was not powered for statistical significance. In Moron Moreau's OWN WORDS, he told the market the study would have needed overwhelming data to move to Phase 3. If you believe Algernon had the means/money to run a real Gold Standard - 2000 patient study to try to get to statistical significance, I have a bridge to sell you.

Had they gotten statistical significance from a Gold Standard Phase 2 clinical trial, Algernon would likely have gotten all kinds of financial help to move forward in their efforts. You cannot get around the fact of having been duped by double talk coming from management.

The two COVID-19 studies in South Korea and Romania were both trash @ss studies that had no chance from the outset. As witnessed by South Korea study never getting off the ground (Schleprock). The data coming from the IPF/Chronic Cough study will be recycled into another Phase 2 study maybe, maybe not. Who knows?

On April Fools Day 2021 this news dropped:

www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#

Take a pass on Algernon Pharmaceuticals, says Mackie

April 1, 2021

The Phase 2b part involving 150 subjects found no dose-dependent response...

On the WHO score, Ifenprodil missed the primary endpoint by showing no difference from the control group...

Commenting on the results, Uddin wrote, “The lack of a dose-dependent effect in a clinical trial normally suggests poor efficacy of a compound. AGN disclosed 40 mg ifenprodil did not show any effects in this study while the 20 mg dose demonstrated some trends. Based on the lack of dose response, we unfortunately would not expect this indication to be advanced.”

April Fools Day…how fitting for the occasion.

Some pennyland dreamers would have been happy if Algernon had advanced a Turkey sandwich with all the trimming into a Phase 3 clinical trial? The odds of success between the two are probably equivalent had Algernon advanced Ifenprodil for COVID-19.





Also, think of the FDA having thrown all caution to the wind for companies willing to spend their money on frivolous studies at every level. The FDA was in a panic over the pandemic. No name (trash @ss dumpster fire) companies came out of the woodwork with pie in the sky studies. 99.9999% of all of them failed.

The odds for Algernon getting to statistical significance at Phase 3 having not done so at Phase 2 sounds like an absolutely ridiculous plan. Among all the fireable offenses to date by management you can be rest assured taking Ifenprodil to a Phase 3 for COVID-19 would have warranted pitch forks marching to whatever addresses they were using at the time.


In response to your other post...

I'm stepping away from the lectern. I remain here simply to receive the FLOPline data readout. Thereafter, I'm a ghost. Others can spin the AGNPF narrative into glitter and gold fairy dust from here on out. The mic is all yours.



M$


PostScript

Cough Trial USA ASAP | Cough Trial Australia ????